$3.65
-0.01[-0.27%]
At close: Apr 24
$3.65
0[0.00%]
After Hours: 4:02PM EDT
Design Therapeutics
(NASDAQ:DSGN)Design Therapeutics Stock (NASDAQ:DSGN), Analyst Ratings, Price Targets, Predictions
Design Therapeutics Inc has a consensus price target of $3.75, established from looking at the 18 latest analyst ratings. The last 3 analyst ratings were released from RBC Capital, Wedbush, and RBC Capital on March 20, 2024, March 20, 2024, and November 14, 2023. With an average price target of $4.33 between RBC Capital, Wedbush, and RBC Capital, there's an implied 18.72% upside for Design Therapeutics Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
RBC Capital
Wedbush
SVB Leerink
Goldman Sachs
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Design Therapeutics
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 03/20/2024 | DSGN | Buy Now | Design Therapeutics | $3.65 | 9.59% | RBC Capital | Leonid Timashev | → $4 | Reiterates | Sector Perform → Sector Perform | Get Alert |
| 03/20/2024 | DSGN | Buy Now | Design Therapeutics | $3.65 | 36.99% | Wedbush | Laura Chico | → $5 | Reiterates | Neutral → Neutral | Get Alert |
| 11/14/2023 | DSGN | Buy Now | Design Therapeutics | $3.65 | 9.59% | RBC Capital | Leonid Timashev | $7 → $4 | Maintains | Sector Perform | Get Alert |
| 08/15/2023 | DSGN | Buy Now | Design Therapeutics | $3.65 | 64.38% | Wedbush | Laura Chico | → $6 | Downgrade | Outperform → Neutral | Get Alert |
| 08/15/2023 | DSGN | Buy Now | Design Therapeutics | $3.65 | 64.38% | SVB Leerink | Joseph Schwartz | → $6 | Downgrade | Outperform → Market Perform | Get Alert |
| 08/15/2023 | DSGN | Buy Now | Design Therapeutics | $3.65 | 91.78% | RBC Capital | Leonid Timashev | $23 → $7 | Downgrade | Outperform → Sector Perform | Get Alert |
| 05/10/2023 | DSGN | Buy Now | Design Therapeutics | $3.65 | 530.14% | RBC Capital | Leonid Timashev | $24 → $23 | Maintains | Outperform | Get Alert |
| 05/10/2023 | DSGN | Buy Now | Design Therapeutics | $3.65 | 420.55% | Wedbush | Laura Chico | $20 → $19 | Maintains | Outperform | Get Alert |
| 05/04/2023 | DSGN | Buy Now | Design Therapeutics | $3.65 | — | Goldman Sachs | Madhu Kumar | — | Upgrade | Sell → Neutral | Get Alert |
| 03/15/2023 | DSGN | Buy Now | Design Therapeutics | $3.65 | 557.53% | RBC Capital | Leonid Timashev | → $24 | Reiterates | → Outperform | Get Alert |
| 12/09/2022 | DSGN | Buy Now | Design Therapeutics | $3.65 | 502.74% | SVB Leerink | Joseph Schwartz | $30 → $22 | Maintains | Outperform | Get Alert |
| 12/08/2022 | DSGN | Buy Now | Design Therapeutics | $3.65 | 557.53% | RBC Capital | Leonid Timashev | $29 → $24 | Maintains | Outperform | Get Alert |
| 08/09/2022 | DSGN | Buy Now | Design Therapeutics | $3.65 | 612.33% | Wedbush | Laura Chico | $21 → $26 | Maintains | Outperform | Get Alert |
| 06/10/2022 | DSGN | Buy Now | Design Therapeutics | $3.65 | 475.34% | Wedbush | Laura Chico | → $21 | Initiates | → Outperform | Get Alert |
| 05/24/2022 | DSGN | Buy Now | Design Therapeutics | $3.65 | 64.38% | Goldman Sachs | Madhu Kumar | $8 → $6 | Maintains | Sell | Get Alert |
| 05/10/2022 | DSGN | Buy Now | Design Therapeutics | $3.65 | 721.92% | SVB Leerink | Joseph Schwartz | $36 → $30 | Maintains | Outperform | Get Alert |
| 05/02/2022 | DSGN | Buy Now | Design Therapeutics | $3.65 | 721.92% | RBC Capital | Leonid Timashev | → $30 | Initiates | → Outperform | Get Alert |
| 01/19/2022 | DSGN | Buy Now | Design Therapeutics | $3.65 | 173.97% | Goldman Sachs | Madhu Kumar | → $10 | Initiates | → Sell | Get Alert |
FAQ
What is the target price for Design Therapeutics (DSGN)?
The latest price target for Design Therapeutics (NASDAQ: DSGN) was reported by RBC Capital on March 20, 2024. The analyst firm set a price target for $4.00 expecting DSGN to rise to within 12 months (a possible 9.59% upside). 9 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Design Therapeutics (DSGN)?
The latest analyst rating for Design Therapeutics (NASDAQ: DSGN) was provided by RBC Capital, and Design Therapeutics reiterated their sector perform rating.
When was the last upgrade for Design Therapeutics (DSGN)?
The last upgrade for Design Therapeutics Inc happened on May 4, 2023 when Goldman Sachs raised their price target to N/A. Goldman Sachs previously had a sell for Design Therapeutics Inc.
When was the last downgrade for Design Therapeutics (DSGN)?
The last downgrade for Design Therapeutics Inc happened on August 15, 2023 when Wedbush changed their price target from N/A to $6 for Design Therapeutics Inc.
When is the next analyst rating going to be posted or updated for Design Therapeutics (DSGN)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Design Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Design Therapeutics was filed on March 20, 2024 so you should expect the next rating to be made available sometime around March 20, 2025.
Is the Analyst Rating Design Therapeutics (DSGN) correct?
While ratings are subjective and will change, the latest Design Therapeutics (DSGN) rating was a reiterated with a price target of $0.00 to $4.00. The current price Design Therapeutics (DSGN) is trading at is $3.65, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.